Page 64 - Sohini Das

Dolo 650 maker says drug part of Covid treatment, denies 'freebie' charges

In paracetamol market, Dolo's share rose to 24% from 15% pre-Covid-19

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet

The recent controversy following income tax raids on Micro Labs, makers of popular paracetamol brand Dolo, is likely to make things move in making the UCPMP

PharmEasy calls off its public offer; to go for rights issue instead

API Holdings, the parent company of PharmEasy, wrote to shareholders announcing withdrawal of DRHP

The pink of health: Trade generics now key growth driver for Cipla

Vertical witnesses 25% CAGR in 5 yrs

Centre proposes anti-dumping duty on China antibiotic drug ofloxacin

No impact on end consumer as prices are regulated

US ranitidine litigation unlikely to impact Indian pharma: Analysts

Sun Pharmaceuticals, Dr Reddy's Laboratories, Perrigo and Teva have agreed to a combined settlement of $5 mn with cancer patient Joseph Bayer

Serum Institute, other firms eye tie-ups to develop monkeypox vaccine

Indian Immunologicals, and Haffkine Research Institute also in the fray

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

SII may use Oxford Biomedica's plant to make malaria, flu vaccines

SII is building a future pandemic facility, which will have an annual capacity of 2 bn doses

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

Seeks nod as both primary and precaution dose

Indian Covid vaccine makers eye regulator nod for universal boosters

Plans afoot to seek regulator nod for universal boosters

Mandatory mask rule, fines back in Delhi as Covid cases rise again

Sharp rise in test positivity rate in Delhi past few weeks; doctors say many admitted for other ailments testing Covid-positive; Mumbai also sees spurt in cases

Glenmark Pharmaceuticals' Q1 net profit drops 31% to Rs 211.1 crore

Adjusted Ebidta was Rs 4,72.6 crore in the quarter ended June 30, 2022 as against Rs 5,73.6 crore in the previous corresponding quarter, with margins of 17 per cent

Biological E's Corbevax gets a boost, as govt allows mixing vaccines

Health ministry nod to the Biological E vaccine as 3rd dose after Covishield or Covaxin, CoWIN to be updated within a week

100-year road map: Pharma industry eyes $400-billion turnover by 2047

The industry is now talking about breaking into the top-10 countries in terms of value by 2030, and entering the top-5 club by 2047

Succession at Torrent Group: Varun Mehta inducted into Torrent Power Board

After cousin Aman joins Torrent Pharma board, Varun Mehta, son of Sudhir Mehta, joins Torrent Power Board

India ramping up monkeypox testing capacity amid rising cases: Here's how

Tapping the TB testing network, screening tests, quick-result PCRs are all in the works

Free booster drive to salvage wastage of coronavirus vaccine doses

Rate of vaccination jumps from 153,000/day to 1.86 million in the 18-59 yr cohort after free booster drive was rolled out

Serum Institute explores new-age vaccine delivery systems for growth

The Pune-based company that manufactured the Covid-19 vaccine administered to most Indians is exploring more sophisticated delivery systems

What is keeping Adar Poonawalla busy these days?

Adar Poonawalla has taken Indian vaccines to the US and European markets. In an interview with Business Standard's Sohini Das, he tells about his plans for mass production of vaccines and more